UK – Novartis’ MS therapy Kesimpta wins NICE backing

Novartis’ Kesimpta has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of relapsing remitting multiple sclerosis (RRMS) in adult patients.

Kesimpta (ofatumumab) is the first self-administered, targeted B-cell therapy licensed for adults with relapsing forms of MS with active disease, according to Novartis.

In its final appraisal document, NICE recommended Kesimpta for the treatment of adult patients with RRMS with active disease, defined by clinical or imaging features.

NICE concluded that Kesimpta is a cost-effective treatment that can be used as a first-line therapy or following the use of other treatments for people with RRMS.

The decision is based on results from the two Phase III ASCLEPIOS studies which both met clinical and magnetic resonance imaging (MRI) endpoints…